Diagnostics company Guardant Health (NASDAQ:GH) in Q2 CY2025, with sales up 30.9% year on year to $232.1 million. The company ...

Guardant Health partners with actor James Van Der Beek to promote early colorectal cancer screening through the Shield blood ...

James Van Der Beek is sharing the subtle colorectal cancer symptom he ignored before his shocking diagnosis. “There wasn’t ...

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its partnership with actor and ...

Exact Sciences is paying $75 million for exclusive rights to a blood-based "liquid biopsy" screening test from rival firm ...

James Van Der Beek was diagnosed with colon cancer in 2023. He hopes more people will get screened earlier with the new ...

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will participate in the ...

Guardant Health is a leader in liquid biopsy. It has market leading platforms in genomics profiling, molecular residual disease, or MRD, testing, and single cancer screening for colorectal cancer ...

Guardant Health has commercially launched Guardant360 ®, Guardant360 ® CDx, Guardant360 TissueNext™, Guardant360 Response™, and GuardantINFINITY™ tests for advanced-stage cancer patients ...

With a stock down nearly 50% over the last 52 weeks, investors in Guardant Health (GH -2.49%) haven't had a lot to cheer about this year. The last couple of days, however, may be changing that.

Guardant Health thinks around 700,000 patients in the U.S. could eventually benefit from advanced-stage cancer screening, which would drive up sales to around $6 billion annually.

If Guardant Health can capture a significant share of these markets, its long-term returns could make the 360% gain since its IPO look like chump change. I think that this stock has the kind of X ...